Repositioning Candidate Details
| Candidate ID: | R1001 |
| Source ID: | DB06399 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Atacicept |
| Synonyms: | Atacicept; Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein (Fc5); TACI-Fc5; TACI-IG |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI. |
| CAS Number: | 845264-92-8 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with certain autoimmune diseases such as systemic lupus erythematosus. Current data indicates that levels of BLyS and APRIL are elevated in patients with rheumatoid arthritis, lupus erythematosus, B-cell malignancies and multiple sclerosis. Atacicept has been shown to affect several stages of B-cell development and may inhibit the survival of cells responsible for making antibodies. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |